A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.

Christopher W KahlerPatricia A CioeGolfo K TzilosNichea S SpillaneLorenzo LeggioSusan E RamseyRichard A BrownStephanie S O'Malley

Published in: Alcoholism, clinical and experimental research (2017)

Results indicate that heavy-drinking smokers, including those with current alcohol dependence, can make substantial reductions in drinking in the context of smoking cessation treatment. However, this study provided no evidence that naltrexone is efficacious for enhancing reductions in drinking or improving smoking cessation in this population. Limitations of this study included lower-than-desired sample size and modest adherence to study medication.

Keyphrases

smoking cessation
replacement therapy
alcohol consumption
healthcare
mental health
randomized controlled trial
type diabetes
open label
metabolic syndrome
placebo controlled
adverse drug
phase iii
glycemic control
alcohol use disorder
drug induced